Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
''Brugmansia'' spp., Angel's trumpet, ''borrachero'', ''toé'' (1) ·
''Cola nitida'', ''Cola acuminata'' (1) ·
''Ilex paraguariensis'' (1) ·
''Ilex vomitoria'' (1) ·
''Paullinia cupana'' (1) ·
''Sophora secundiflora''. Texas mountain laurel, frijolillo (1) ·
''Theobroma cacao'' (1) ·
Caplyta (1) ·
Deadly nightshade (1) ·
Henbane, black henbane (1) ·
Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK) (1) ·
Lovaza, Omtryg (1) ·
Mandrake (1) ·
Nuplazid (1) ·
Qelbree (1) ·
REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) ·
Rexulti (1) ·
The ayahuasca vine, ''yagé'', ''caapi'', ''mariri'' (1) ·
Trintellix (US), Brintellix (formerly) (1) ·
Viibryd (1) ·
Wormwood, absinthe, la Fée Verte, the Green Muse (1)
classes:
5HT1A activity than aripiprazole (1) ·
5HT2A (1) ·
5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity (1) ·
Atypical antipsychotic (2) ·
Caffeine plant (5) ·
D2/5HT1A partial agonist with stronger α1A (1) ·
Daimonica (4) ·
Excitantia (5) ·
low-trapping) (1) ·
MAOI (1) ·
Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist (1) ·
NMDA receptor antagonist (uncompetitive (1) ·
non-stimulant ADHD agent (1) ·
Phantastica (2) ·
Plant Medicine (12) ·
Rhapsodica (1) ·
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) (1) ·
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1) ·
Serotonin partial agonist reuptake inhibitor (SPARI) (1) ·
Tropane alkaloid plant (4) ·
[[:Category:Antimanic medicines|Antimanic]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (1) ·
[[:Category:Mood stabilizers|Mood stabilizer]] (1) ·
[[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]] (1)
mechanism:
None (5) ·
Active alkaloid is cytisine, a nicotinic acetylcholine receptor agonist. NOT a classical 5-HT2A psychedelic. (1) ·
Active principle is thujone, a GABA-A antagonist (the opposite of most CNS depressants). Also present in cooking sage (''Salvia officinalis''), tansy, and ''Thuja'' cedars. (1) ·
Caffeine (1.5–2%) + theobromine + kolanin (a glycoside). (1) ·
Caffeine (highest of the ''Ilex'' genus) plus saponins that produce ritual vomiting at high doses. (1) ·
Caffeine (sometimes called 'mateine' historically, though chemically identical), theobromine, theophylline, plus polyphenols. (1) ·
Contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, reversible monoamine oxidase inhibitors (RIMAs) that allow oral DMT to reach the brain. (1) ·
Highest natural caffeine content of any plant (2–7% by dry weight, ~2–4× coffee). Caffeine is bound to tannins, producing a slower release than pure coffee caffeine. (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Primary alkaloid is theobromine (3,7-dimethylxanthine), with minor caffeine. Also contains phenethylamine, anandamide (an endogenous cannabinoid), tryptophan (serotonin precursor), and flavanols. The combined effect is mild stimulation + mood elevation. (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1) ·
Tropane alkaloids: hyoscyamine (dominant; the racemic form is atropine), scopolamine. Competitive muscarinic antagonism. (1) ·
Tropane alkaloids: hyoscyamine, scopolamine, atropine, apoatropine. (1) ·
Tropane alkaloids: hyoscyamine, scopolamine, in higher seed concentrations than belladonna or datura. (1) ·
Tropane alkaloids: scopolamine (dominant), hyoscyamine, atropine. Competitive antagonism at muscarinic acetylcholine receptors. (1) ·
'"`UNIQ--vote-0000004E-QINU`"' The EPA+DHA mix is biochemically and clinically distinct from icosapent ethyl'"`UNIQ--ref-0000004F-QINU`"'. (1)
uses:
None (1) ·
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
Investigational for major depressive disorder; trials underway (phase 3 mixed results) (1) ·
Major depressive disorder in adults (FDA-approved 2011) (1) ·
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants. (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1) ·
'"`UNIQ--vote-00000006-QINU`"' (2) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (5) ·
'"`UNIQ--vote-00000050-QINU`"' (1) ·
'"`UNIQ--vote-00000065-QINU`"' (1) ·
'"`UNIQ--vote-000000AD-QINU`"', '"`UNIQ--vote-000000AE-QINU`"' (1) ·
'"`UNIQ--vote-000003A0-QINU`"', '"`UNIQ--vote-000003A1-QINU`"' (1) ·
'"`UNIQ--vote-0000069B-QINU`"', '"`UNIQ--vote-0000069C-QINU`"' (1) ·
'"`UNIQ--vote-0000081E-QINU`"' (1)
starting dose:
None (12) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) ·
34 mg PO once daily (1) ·
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) ·
42 mg PO once daily with food (no titration) (1) ·
A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual) (1) ·
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Trials use 25 mg or 50 mg PO daily (1)
preparations:
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
10 mg, 34 mg capsules/tablets (1) ·
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) ·
42 mg capsules (1) ·
5 mg, 10 mg, 20 mg tablets (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Dried leaves and twigs, infused in a gourd (''mate'') and drunk through a metal straw (''bombilla'') (1) ·
Dried leaves; absinthe liqueur (120–160 proof, with hyssop, lemon balm, fennel, anise, sometimes Acorus calamus) (1) ·
Fermented and roasted seeds, ground. Mexican tradition: drunk with chili, cornmeal, achiote. European tradition: with sugar and milk (1) ·
Flowers or leaves infused or smoked. Highly variable potency; narrow toxic margin (1) ·
Fresh nuts chewed; also dried and powdered (1) ·
Investigational oral capsule (1) ·
Leaves and seeds, traditionally smoked or infused. Possibly the original Pythia oracle plant (1) ·
Leaves, berries, root. Historically: belladonna cigarettes ("Asthmador") OTC in US until the 1970s (1) ·
Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets. (1) ·
Roasted seeds ground to powder, mixed with water; commercial syrups and energy drinks (1) ·
Root, traditionally carved into ''mannikens'' or infused into wine (1) ·
Toasted leaves and twigs decocted to a near-black concentrate (1)
fda max:
None (12) ·
20 mg/d (1) ·
34 mg/d (1) ·
4 g/d (1) ·
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) ·
40 mg/d (1) ·
400 mg/d (pediatric); 600 mg/d (adult) (1) ·
42 mg/d (1) ·
No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.'"`UNIQ--ref-00000052-QINU`"' (1) ·
Not yet approved (1)
routes: (Click arrow to add another value)
onset:
None (12) ·
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) ·
Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.'"`UNIQ--ref-00000053-QINU`"' (1) ·
Antipsychotic effect over weeks (1) ·
Benefit over weeks of dosing (1) ·
Rapid (within 1 week in trials) (1) ·
Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) ·
Typical antidepressant 4-6 week onset (1) ·
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)
duration: (Click arrow to add another value)
halflife:
None (12) ·
Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.'"`UNIQ--ref-00000055-QINU`"' (1) ·
Not formally established (1) ·
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) ·
~18 hours (terminal) (1) ·
~25 hours (1) ·
~57 hours (parent), ~200 h (active metabolite) (1) ·
~66 hours (1) ·
~7 hours (1) ·
~91 hours (1)
bioavailability:
None (13) ·
Adequate oral bioavailability with extended-release formulation (1) ·
Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) ·
Limited but adequate; take with food (1) ·
Not characterized; oral dosing once daily (1) ·
Oral bioavailability suitable for daily dosing (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~75% (1) ·
~95% (1)
pregnancy:
None (13) ·
Investigational (1) ·
Limited data (1) ·
Limited data; avoid (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) ·
Limited data; weigh benefits/risks (2) ·
Limited human data<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (10) ·
Currently legal in most jurisdictions with thujone limits (1) ·
Investigational (1) ·
Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified. (1) ·
Plant unrestricted; pharmaceutical atropine Rx-only (1) ·
Rx (4) ·
Rx, '''not a controlled substance''' (no DEA scheduling) (1) ·
Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1)
Showing below up to 21 results in range #1 to #21.